₹4,000 weight-loss shots are coming to India. The real shift is what comes with them
TNN / Mar 20, 2026, 12:39 (IST)
As semaglutide’s patent expires on March 20 the entry of generics is set to nearly halve treatment costs, opening up injectable anti-obesity treatment. But pharma firms, trying to stand out in a crowded room, are looking beyond simple price cuts, eyeing an entire weight-loss ecosystem. This could include diet plans, counselling and clinic partnerships